Vimarsana
Biggest News Aggregation in the World

Page 3 - Controlled Equity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Controlled Equity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Controlled Equity Today - Breaking & Trending Today

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND : COMMON SHARES (PAR VALUE $0.01 PER SHARE) THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT - Form 8-K - Vimarsana News

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND : COMMON SHARES (PAR VALUE $0.01 PER SHARE) THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT - Form 8-K

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND COMMON SHARES THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT ... | April 11, 2023

BioVie : Sales Agreement - Form 8-K | MarketScreener - Vimarsana News

BioVie : Sales Agreement - Form 8-K | MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13... | April 7, 2023

ALTUS POWER, INC. : Entry into a Material Definitive Agreement (form 8-K) - Vimarsana News

ALTUS POWER, INC. : Entry into a Material Definitive Agreement (form 8-K)

Item 1.01. Entry into a Material Definitive Agreement. On April 6, 2023, Altus Power, Inc, a Delaware corporation , entered into a Controlled Equity OfferingSM Sales Agreement ... | April 6, 2023

SCYNEXIS : 10-K Filing | MarketScreener - Vimarsana News

SCYNEXIS : 10-K Filing | MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ... | March 31, 2023

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Zynerba - Vimarsana News

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Zynerba

* Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 * European Commission granted orphan... | March 29, 2023